Neocate Syneo

Neocate: 35 years reinvesting into CMA research and innovation

>95 clinical studies published on Neocate and its use in CMA, multiple food protein allergy (MFPA) and other conditions requiring an amino acid-based diet.

Breast milk is the best source of nutrition for infants with CMA^7,8

Nutrition during the first months of life has a significant influence on the development and composition of the gut microbiota.⁵ Research shows that the gut microbiota plays an important role in the development of the immune system.⁹

Breast milk contains all the essential nutrients to support an infant's growth and development. It contains pre- and probiotics to stimulate a healthy gut microbiota and support the developing immune system.^10,11 Breastfeeding has been shown to reduce the risk of allergic disease.^12,13

Breastfed infants benefit from the synergistic effect of prebiotic oligosaccharides and beneficial bacteria naturally present in breast milk

• Supporting a healthy, diverse gut microbiota^11,14,15
• Promoting tolerance and developing the immune response^10,16,17

Only Neocate Syneo contains synbiotics, bringing it closer to breast milk than any other AAF¹

The synbiotics in Neocate Syneo have been developed through extensive research of pre- and probiotics and tested in allergic infants,^1-4 who commonly have lower levels of Bifidobacteria than healthy infants.^18–22

Synbiotics are a patented combination of pre- and probiotics in a synergistic relationship.

Evidence shows that synbiotics positively influence the gut microbiota of allergic infants, bringing it closer to that of a healthy breastfed infant.¹

Neocate Syneo is the only AAF with consistent high-quality evidence in cow’s milk allergic infants, the intended patient group^1-4,34

Supported by randomised clinical trials, Neocate Syneo has shown unique benefits supported by extensive research:

• Brings the gut microbiota closer to that of healthy breastfed infants (ASSIGN) ^1-3
• Is hypoallergenic and well tolerated^3,4
• Fewer reported infections and less antibiotic use^1-3,34

The ASSIGN trial shows that Neocate Syneo brings the gut microbiota of allergic infants closer to that of healthy breastfed infants.^1,2

• There was a sustained improvement in the gut microbiota composition of allergic infants over 26 weeks.^1,2 Evidenced by a significant growth of Bifidobacterium in line with levels seen in healthy breastfed infants and the competitive inhibition of pathogenic bacteria^1,2
• Certain species of microbes, such as Bifidobacteria, support the development of the immune system and promote oral tolerance^4,5

Exploratory outcomes from research show that infants receiving Neocate Syneo exhibit a reduction in infections^1–3 as well as antibiotic^1,2 use.

Fewer infections

Exploratory outcomes from research shows that infants receiving Neocate Syneo exhibit a reduction in infections as well as antibiotic use, compared to infants receiving a regular AAF without synbiotics.^1–3

1. Candy DCA et al. Pediatr Res. 2018;83(3):677-86.
2. Fox AT et al. Clin Transl Allergy. 2019;9:5.
3. Burks AW et al. Ped Allergy Immunol. 2015;26:316-22.
4. Martin R et al. Benef Microbes. 2010;1(4):367-82.
5. Wopereis H et al. Pediatr Allergy Immunol. 2014;25:428-38.
6. Harvey BM et al. Pediatr Res. 2014;75:343-51.
7. WHO. Infant and young child feeding. 2003.
8. Jeurink PV et al. Benef Microbes. 2013;4(1):17-30.
9. Weng M et al. J Dev Orig Health Dis. 2013;4(3):203-14.
10. Boehm G et al. J Nutr. 2007;137:8475-95.
11. Moossavi S et al. Front Pediatr. 2018;6:197.
12. Kull I et al. Arch Dis Child. 2002;87:478-81.
13. Matheson MC et al. J Allergy Clin Immunol. 2007;120(5):1051-57.
14. Scholtens PA et al. Annu Rev Food SciTechnol. 2012;3:21.1:21-23.
15. Hunt KM et al. PLoS ONE. 6(6): e21313. doi:10.1371.
16. Li M et al. Semin Reprod Med. 2014;32:74–86.
17. Kaplan JL et al. Pediatr Res. 2011;69:465–72.
18. Kirjavainen PV. Gut. 2002;51:51–55.
19. Huang YJ et al. J Allergy Clin Immunol. 2017;139(4):1099-1110.
20. Azad MB et al. Clin Exp Allergy. 2015;45:632-43.
21. Bisgaard H et al. J Allergy Clin Immunol. 2011;128:646-52.e1-5.
22. Abrahamsson TR et al. J Allergy Clin Immunol. 2012;129:434-40,40.e1-2.
23. Kunz C et al. AnnuRev Nutr. 2000;20:699-722.
24. Knol J. J Pediatr Gastroenterol Nutr. 2005;40(1):36-42.
25. Moro G. J Pediatr Gastroenterol Nutr. 2002;34(3):291-5.
26. Taniuchi S et al. The Journal of Applied Research. 2005;5(2):387-396.
27. Soto A et al. J Pediatr Gastroenterol Nutr. 2014;59(1):78–88.
28. Thompson-Chagoyan OC et al. Pediatr Allergy Immunol. 2010;21:e394-400.
29. Mikami K et al. Pharmaceuticals. 2012;(5)629-42.
30. Inoue Y et al. Biol Pharm Bull. 2009;32(4):760–63.
31. Hougee S et al. Int Arch Allergy Immunol. 2010;151(2):107–17.
32. Van Esch B et al. Immun Inflamm Dis. 2016;4(2):155–65.
    
33. Hattori K et al. Arerugi. 2003;52(1):20–30.
34. Chatchatee P et al. 2019 Abstract at EAACI PAAM.
35. Commission Delegated Regulation (EU) 2016/128 (FSMP) and Commission Delegated Regulation (EU) 2016/127 (the specific compositional and information requirements for infant formula and follow-on formula)